Cytokinetics Inc
(NAS:CYTK)
$
48.98
-10.25 (-17.31%)
Market Cap: 5.14 Bil
Enterprise Value: 5.27 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 43/100 Cytokinetics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2022 / 09:40PM GMT
Release Date Price:
$39.29
(-0.53%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. Thanks, everyone, for joining us this afternoon. I'm glad you guys can join us at the Goldman Sachs Global Healthcare Conference. We're really thrilled to be joined by Robert Blum, CEO of Cytokinetics. So thanks for joining us, Robert.
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Thank you very much.
Questions & Answers
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst
Right. So I'm going to take the prerogative to toss in a question that is very topical -- related to the drug aficamten for obstructive hypertrophic cardiomyopathy. A lot of amount of data this morning on the presented at the medical meeting. Can you walk through that data to think about that data in the context of aficamten in its body profile?
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Sure. So the data
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot